Sharon L. Walmsley
Expertise in
8
conditions

Sharon L. Walmsley

Toronto, ON, CA 
Expertise in
8
conditions
Toronto, ON, CA 

Overview

Sharon Walmsley practices practicing medicine in Toronto, Canada.

Ms. Walmsley is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses HIV/AIDS, Hepatitis C, AIDS Dysmorphic Syndrome, and Syphilis.

She is actively involved in clinical research, co-authoring 228 peer reviewed articles and participating in 9 clinical trials.

Gender

Female

Locations

Toronto, ON, Canada
Other Locations
Vancouver, BC, Canada
Toronto, Canada
C.T. Lamont Primary Health Care Research Centre, Ont, Ottawa, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Bone Health in Aging HIV Infected Women: Improvement or Prevention of Changes in Bone Mineral Density by Switching Antiretroviral Agents. Is There an Optimal Time to Intervene?
Bone Health in Aging HIV Infected Women: Improvement or Prevention of Changes in Bone Mineral Density by Switching Antiretroviral Agents. Is There an Optimal Time to Intervene?
Enrollment Status: Completed
Publish Date: December 19, 2024
Intervention Type: Drug
Study Drugs: tenofovir-alafenamide-emtricitabine, tenofovir-emtricitabine
Study Phase: Phase 4
A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A, an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naïve HIV-1-Infected Adults
A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A, an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naïve HIV-1-Infected Adults
Enrollment Status: Completed
Publish Date: October 15, 2024
Intervention Type: Biological
Study Drug: GSK3810109A
Study Phase: Phase 2
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
Cognitive Remediation Group Therapy to Improve Older Adults' Ability to Cope With HIV-Associated Neurocognitive Disorder (HAND)
Cognitive Remediation Group Therapy to Improve Older Adults' Ability to Cope With HIV-Associated Neurocognitive Disorder (HAND)
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Tenofovir alafenamide based regimen
Study Phase: Phase 3
COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir
COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir
Enrollment Status: Unknown
Publish Date: December 14, 2021
Intervention Type: Drug
Study Drug: Lopinavir/ritonavir
Study Phase: Phase 3
Enhanced Syphilis Screening Among HIV-positive Men (ESSAHM): Evaluation of a Clinic-based Intervention
Enhanced Syphilis Screening Among HIV-positive Men (ESSAHM): Evaluation of a Clinic-based Intervention
Enrollment Status: Completed
Publish Date: July 26, 2018
Intervention Type: Other
Study Phase: Not Applicable
Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial
Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial
Enrollment Status: Completed
Publish Date: April 19, 2018
Intervention Type: Drug
Study Phase: Phase 2
Probiotic Visbiome for Inflammation and Translocation in HIV I (PROOV IT I)
Probiotic Visbiome for Inflammation and Translocation in HIV I (PROOV IT I)
Enrollment Status: Terminated
Publish Date: March 01, 2018
Intervention Type: Other, Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

227 Total Publications

Post-Traumatic Stress Symptoms Related to the COVID-19 Pandemic in Persons Living and Aging with HIV.
Post-Traumatic Stress Symptoms Related to the COVID-19 Pandemic in Persons Living and Aging with HIV.
Journal: AIDS research and human retroviruses
Published: July 24, 2026

Frequently Asked Questions about Sharon L. Walmsley

Is Sharon L. Walmsley a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Sharon L. Walmsley is classified as an Elite expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sharon L. Walmsley participate in research or clinical trials?

Yes. Sharon L. Walmsley has published 227 articles and abstracts on conditions like HIV/AIDS. You can view a list of Sharon L. Walmsley's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Walmsley's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile